Compare Recursion Pharmaceuticals Inc (RXRX) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vistra Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.32 (market cap $1.78B), while Vistra Corp trades at $145.55 (market cap $47.95B). The key difference: Vistra Corp is far larger — about 26.9× Recursion Pharmaceuticals Inc's market cap, and Vistra Corp pays a 0.64% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | VST | |
|---|---|---|
Market Cap | $1.78B | $47.95B |
Sector | Health | Technology |
52-Week High | $6.79 | $217.92 |
52-Week Low | $2.84 | $134.71 |
Enterprise Value | $1.30B | $69.89B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Vistra (VST) trades at $140.59, down 0.56% on the day, with a bearish technical signal driven by selling pressure in moving averages. The stock shows strong profitability with a net income margin of 11.55% and ROE of 75.73%, though recent quarterly EPS results were mixed with two misses against expectations. Analyst consensus remains overwhelmingly bullish with a 90.91% buy rating and a $239.75 price target, highlighting growth potential from data center electricity demand.
The outlook is supported by strategic positioning in power generation for AI infrastructure, but risks include volatile hedging impacts and high P/B valuation. Earnings growth from hyperscaler deals and nuclear assets offers upside, while technical weakness near support at $136 requires monitoring for stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
